COVID-19: High-JAKing of the Inflammatory “Flight” by Ruxolitinib to Avoid the Cytokine Storm

COVID-19: High-JAKing of the Inflammatory “Flight” by Ruxolitinib to Avoid the Cytokine Storm

Since SARS-CoV-2 outbreak in December 2019, world health-system has been severely impacted with increased hospitalization, Intensive-Care-Unit (ICU) access and high mortality rates, mostly due to severe acute respiratory failure and multi-organ failure. Excessive and uncontrolled release of proinfla...

Full description

Bibliographic Details
Main Authors: Cirino Botta, Alessia Indrieri, Eugenio Garofalo, Flavia Biamonte, Andrea Bruni, Pino Pasqua, Francesco Cesario, Francesco Saverio Costanzo, Federico Longhini, Francesco Mendicino
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-01-01
Series:Frontiers in Oncology
Subjects:
COVID-19
ruxolitinib
hyperinflammation
ferritin
JAK2
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2020.599502/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2020.599502/full

Similar Items